Navigation Links
Medtronic, Inc. and Medtronic Sofamor Danek, USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC

ATLANTA, Dec. 3 /PRNewswire/ -- A patient who was surgically implanted with Medtronic's Infuse(R) Bone Graft product, for an off-label use promoted by Medtronic, suffocated due to severe throat and neck swelling, according to James A. Dunlap Jr. & Associates LLC and Page Perry, LLC who filed the lawsuit in California along with another national law firm.

The Complaint alleges, among other things, that Medtronic improperly promoted its Infuse(R) Bone Graft product for a cervical lumbar surgery procedure, when the product was not approved by the Food and Drug Administration for that use. Infuse(R) Bone Graft product may cause severe swelling in the neck and throat that restricts breathing and can lead to suffocation of the patient if used off-label for unapproved uses, particularly spinal surgery performed from the back.

"The Nisbet family is grieving the loss of Mrs. Nisbet, a beloved wife and mother," said James A. Dunlap, one of the attorneys representing the Nisbet family. "Because of Medtronic's wrongful conduct, many other patients like Shirley Nisbet may have improperly received Medtronic's Infuse(R) Bone Graft product for an off-label use," Mr. Dunlap added.

The FDA has received more than 200 reports of significant side effects resulting from off-label use of the medical device, particularly in the cervical spine, a number of which have led to serious and potentially life- threatening complications. According to the FDA, complications typically occur within two to 14 days after the implant surgery. Some individuals required insertion of feeding tubes, tracheotomies, anti-inflammatory drugs and additional surgery to drain the implant site. Data presented at a recent spine conference reflected a 59 percent complication rate in cervical spinal surgeries using Infuse(R). The study was conducted by a group of North Carolina surgeons between July 2005 and December 2007 and involved 76 patients.

Medtronic's Infuse(R) Bone Graft product has been the subject of a recent whistleblower lawsuit brought by former Medtronic employees who alleged that doctors received over $8 million in 2006 in "sham" consulting fees for using and promoting the Infuse(R) Bone Graft product. Medtronic's marketing and promotion of the device for off-label uses is being investigated by the United States Department of Justice. In addition, the United States Senate is conducting hearings into the matter. Medtronic previously settled for $40 million with the Justice Department on another whistleblower action alleging that, between 1998 and 2003, Medtronic's spinal products division paid kickbacks to doctors in a number of forms, including sham consulting agreements, sham royalty agreements and lavish trips to desirable locations.

The case is "Walter Nisbet et al. v. Medtronic, Inc. and Medtronic Safamor Danek USA, Inc., United States District Court, Central District of California, Case No. SACV08-1361-JVS (RNBx)."

For additional information contact James A. Dunlap Jr. & Associates LLC at 404-354-2363,, or Page Perry, LLC, at 770-673-0047,

SOURCE James A. Dunlap Jr. & Associates LLC; Page Perry, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
2. Shareholder Class Action Filed Against Medtronic, Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Supreme Court Hears Case on Federal Pre-emption of Safety Standards for Medical Technologies (Riegel v. Medtronic, Inc.)
4. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
5. Court Rejects Two Medtronic Patents
6. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
7. Medtronic Celebration of Courage Set for September 13th
8. Medtronic Spine, Formerly Kyphon Inc., to Pay U.S. $75 Million to Resolve Allegations Of Defrauding Medicare
9. Medtronic Mediterranean Launches Worlds First Arabic-Language Integrated Insulin Therapy for Improved Diabetes Management
10. Wolf Popper Announces Filing of Securities Class Action Lawsuit Against Medtronic Inc. - MDT
11. Another Medtronic Sprint Fidelis Lead Lawsuit is Filed in Federal District Court
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... Additional breast cancers found with MRI ... to a study published online in the journal Radiology. Researchers said that in ... a change in treatment. , Breast MRI is the most sensitive technique for ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
(Date:11/25/2015)... ... 2015 , ... The holiday season is jam-packed with family ... of attendees is of the utmost importance. Whether you are cooking at home ... recipes a try this holiday season. , Turkey Croquettes ,     Ingredients: ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of the ... stellar workplace culture with the company’s Cincinnati office being named a finalist among ... was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... global healthcare industry is expected to grow at a rate ... has the highest projected growth at 12.7%, and ... is second with growth projected at 11.5%. ... 2013-2014, total government funded healthcare was nearly 68%. Federal government ... 2013-2014. In real terms, out of pocket expenditure increased by ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
Breaking Medicine Technology: